Pneumococcal pneumonia presenting with septic shock: Host- and pathogen-related factors and outcomes

Thorax

Volumn 65, Issue 1, 2010, Pages 77-81

  Garcia Vidal, C ^a   Ardanuy, C ^a   Tubau, F ^a   Viasus, D ^a   Dorca, J ^a   Linares J ^a   Gudiol, F ^a   Carratala J ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CHLORAMPHENICOL; COTRIMOXAZOLE; ERYTHROMYCIN; HYPERTENSIVE FACTOR; INFLUENZA VACCINE; LEVOFLOXACIN; MACROLIDE; PNEUMOCOCCUS VACCINE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ADULT; AGED; ALCOHOL CONSUMPTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIGEN DETECTION; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL STRAIN; BACTERIUM CULTURE; CHRONIC DRUG ADMINISTRATION; CIGARETTE SMOKING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; GENOTYPE; GRAM STAINING; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; INTENSIVE CARE UNIT; LEGIONELLA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTIC SHOCK; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SYSTOLIC BLOOD PRESSURE; URINALYSIS; VACCINATION;

EID: 73449104256     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.123612     Document Type: Article

References (36)

1. Ardanuy C, Tubau F, Pallarés R, et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction 1997-2007. Clin Infect Dis 2009;48:57-64.
2. Shariatzadeh MR, Huang JQ, Tyrrell GJ, et al. Bacteremic pneumococcal pneumonia: a prospective study in Edmonton and neighboring municipalities. Medicine (Baltimore) 2005;84:147-61.
3. Rosón B, Carratalà J, Dorca J, et al. Etiology, reasons for hospitalization, risk classes and outcomes of patients with community-acquired pneumonia hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001;33:158-65.
4. Feikin DR, Schuchat A, Kolczak M. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90:223-9.
5. Van Der Poll T, Opal S. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008;8:32-43.
6. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995;33:2759-62.
7. Kamerling JP. Pneumococcal polysaccharides: a chemical view. In: Tomasz A, ed. Streptococcus pneumoniae, molecular biology and mechanisms of disease. New York: Mary Ann Liebert, 2000:81-114.
8. Muller-Graf CDM, Whatmore AM, King SJ, et al. Population biology of Streptococcus pneumoniae isolated from oropharyngeal carriage and invasive disease. Microbiology 1999;145:3283-93.
9. Enright MC, Spratt BG. Multilocus sequence typing. Trends Microbiol 1999;7:482-7.
10. Llull D, Lopez R, Garcia E. Clonal origin of the type 37 Streptococcus pneumoniae. Microb Drug Resist 2000;6:269-75.
11. Enright MC, Spratt BG. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 1998;144:3049-60.
12. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
13. Clinical Laboratory Standard Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 19th informational supplement. CLSI document M100-S18. Wayne, PA: CLSI, 2009.
14. Clinical and Laboratory Standard Institute (CLSI). Methods for dilution antimicrobial susceptibility test for bacteria that growth aerobically; approved standard: 7th edn. CLSI documentM7-A6. Wayne, PA: CLSI, 2006.
15. Fenoll A, Granizo JJ, Aguilar L, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009;47:1012-20.
16. McGee L, McDougal L, Zhou J, et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol 2001;39:2565-71.
17. Mortensen E, Coley C, Singer D, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team Cohort Study. Arch Intern Med 2002;162: 1059-64.
18. Kark JD, Lebiush M, Rannon L. Cigarette smoking as a risk factor for epidemic a(h1n1) influenza in young men. N Engl J Med 1982;307:1042-6.
19. Bates Mn, Khalakdina A, Pai M, et al. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med 2007;167:335-42.
20. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995;333:845-51.
21. Straus WL, Plouffe JF, File TM Jr, et al. Risk factors for domestic acquisition of legionnaires' disease. Arch Intern Med 1996;156:1685-92.
22. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000;342:681-9.
23. Chen H, Cowan M, Hasday J, et al. Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-κB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J Immunol 2007;179:6097-106.
24. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002;2:372-7.
25. McCrea KA, Ensor JE, Nall K, et al. Altered cytokine regulation in the lungs of cigarette smokers. Am J Respir Crit Care Med 1994;150:696-703.
26. Cooper M, Stewart P. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:727-34.
27. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964;60:759-70.
28. Henriques B, Kalin M, Ortqvist A, et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in five countries. J Infect Dis 2000;182:833-9.
29. Finland M, Barnes MW. Changes in occurrence of capsular serotypes of Streptococcus pneumoniae at Boston City Hospital during selected years between 1935 and 1974. J Clin Microbiol 1977;5:154-66.
30. Gransden WR, Eykyn SJ, Phillips I. Pneumococcal bacteraemia: 325 episodes diagnosed at St. Thomas's Hospital. BMJ 1985;290:505-8.
31. Martens P, Worm SW, Lundgren B, et al. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect Dis 2004;4:21.
32. Jansen A, Rodenburg G, Van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009;49:e23-29.
33. Alanee SRJ, McGee L, Jackson D, et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 2007;45:46-51.
34. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006;19:571-82.
35. Garcia-Vidal C, Fernández-Sabé N, Carratalà J, et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J 2008;32:733-9.
36. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-41.